News | January 31, 2022
Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
Subscribe To Our Newsletter & Stay Updated
